The use of granulocyte colony-stimulating factor (G-CSF) reduces the severity and duration of neutropenia following myelosuppressive chemotherapy, and prophylaxis has been shown to significantly decrease the risk of FN in patients [2,5]. Here, CSF3 is linked to neutropenia.